News from immatics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

14 Oct, 2014, 08:00 BST EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer

Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC) First centers to enroll glioblastoma...


16 Jul, 2014, 08:00 BST immatics Receives €22 Million Final Tranche of Series D Fundraising

Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the...


13 Nov, 2013, 09:00 GMT immatics and Roche Sign Cancer Vaccine and Immunotherapy Collaboration

Collaboration spans the discovery, development and commercialisation of cancer vaccines and other cancer immunotherapies in gastric, lung and...


15 Oct, 2013, 08:00 BST immatics Closes €34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer

immatics' lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015 Funding secured within existing investor group...


04 Jul, 2013, 08:00 BST New EU-funded Consortium to Develop Fully Personalized Cancer Vaccines for Brain Cancer Patients

Glioma Actively Personalized Vaccine Consortium (GAPVAC): 14 organizations in Europe and the US join forces to develop a completely novel approach to ...


12 Nov, 2012, 08:00 GMT immatics Appoints Peter Chambré as Chairman

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer,...


08 Nov, 2012, 08:00 GMT immatics' Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted US Orphan Drug Designation by the FDA

immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer,...


29 Jul, 2012, 18:00 BST immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine: Immune Response Associates With Longer Survival

Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC) IMA901 is currently being evaluated in a pivotal phase 3 ...


25 May, 2012, 08:00 BST immatics Wins 2012 TiE50 Award

immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network immatics biotechnologies GmbH, a...


15 Jun, 2011, 08:00 BST First Patients are Vaccinated in IMPRINT*, immatics' Pivotal Phase III Trial With IMA901 in Patients With Renal Cell Carcinoma (RCC)

igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced...


11 Apr, 2011, 08:00 BST immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer,...